---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-023753"
form_type: "8-K"
ticker: "CHRN"
cik: "0001549084"
company_name: "EKSO BIONICS HOLDINGS, INC."
filed_at: "2024-07-29T23:59:59+00:00"
generated_at: "2026-05-31T15:42:31.022032+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Ekso Bionics reports record Q2 sales of $5.0M; net loss narrows to $0.13 per share

## Summary
- Revenue $5.0M up 5% YoY; gross margin improved to 53% from 48%.
- Net loss $2.4M ($0.13/sh) vs $4.2M ($0.31/sh) in Q2 2023, narrowing significantly.
- Sold 37 EksoHealth devices in Q2; initial Medicare claims for Ekso Indego Personal pending.
- Operating expenses decreased across all categories: SG&A down 21%, R&D down 20%, G&A down 28%.
- Cash at June 30, 2024 $5.9M, down from $8.6M at Dec 31, 2023.

## SEC filing metadata
- accession: 0001437749-24-023753
- form_type: 8-K
- ticker: CHRN
- cik: 0001549084
- company_name: EKSO BIONICS HOLDINGS, INC.
- filed_at: 2024-07-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1549084/000143774924023753/0001437749-24-023753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1549084/000143774924023753/ekso20240726c_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-023753
- JSON: https://secwatch.observer/filing/0001437749-24-023753.json
- Plain text: https://secwatch.observer/filing/0001437749-24-023753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.